Patents by Inventor Roger Remillard

Roger Remillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20230242535
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: September 2, 2022
    Publication date: August 3, 2023
    Inventors: Jacques Banville, Roger Rémillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10822343
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: November 3, 2020
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20200123160
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: April 23, 2020
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10428077
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 1, 2019
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20180305376
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10047103
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 14, 2018
    Assignees: Bristol-Myers Squibb Company, Universite de Montreal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20170247395
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Jaques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestly, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 9688695
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 27, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jacques Banville, Roger Rémillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20150094297
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 2, 2015
    Inventors: Jacques Banville, Roger Rèmillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • HIV integrase inhibitors
    Patent number: 7893055
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: February 22, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Chen Li, Katharine A. Grant-Young, John D. Matiskella, B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Carl Ouellet, Annapurna Pendri, Roger Remillard, Yasutsugu Ueda, Ting T. Yin
  • N-[[4-fluoro-2-(5-methy-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4-,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor
    Patent number: 7511037
    Abstract: The invention encompasses a series of bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: March 31, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
    Patent number: 7494984
    Abstract: The invention encompasses a series of bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: February 24, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Roger Remillard, Serge Plamondon
  • HIV Integrase Inhibitors
    Publication number: 20080004265
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: June 26, 2007
    Publication date: January 3, 2008
    Inventors: Michael A. Walker, Chen Li, Katharine A. Grant-Young, John D. Matiskella, B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Carl Ouellet, Annapurna Pendri, Roger Remillard, Yasutsugu Ueda, Ting T. Yin
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7192948
    Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: March 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Gilles Bouthillier, B. Narasimhulu Naidu, Roger Remillard, Michael A. Walker
  • Bicyclic heterocycles as HIV-integrase inhibitors
    Publication number: 20070049606
    Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: August 29, 2006
    Publication date: March 1, 2007
    Inventors: Jacques Banville, Roger Remillard, Serge Plamondon
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7176196
    Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7157447
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: January 2, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Bicyclic heterocycles as HIV integrase inhibitors
    Publication number: 20060276466
    Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: August 16, 2006
    Publication date: December 7, 2006
    Inventors: B. Naidu, Jacques Banville, Francis Beaulieu, Timothy Connolly, Mark Krystal, John Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret Sorenson, Yasutsugu Ueda, Michael Walker
  • HIV integrase inhibitors
    Patent number: 7109186
    Abstract: The present invention describes novel compounds of Formula I which inhibit HIV integrase.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: September 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Zhuping Ma, B. Narasimhulu Naidu, Margaret E. Sorenson, Annapurna Pendri, Jacques Banville, Serge Plamondon, Roger Remillard
  • Bicyclic heterocycles as HIV integrase inhibitors
    Publication number: 20060199956
    Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: November 29, 2005
    Publication date: September 7, 2006
    Inventors: B. Naidu, Jacques Banville, Francis Beaulieu, Timothy Connolly, Mark Krystal, John Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret Sorenson, Yasutsugu Ueda, Michael Walker